Heron Therapeutics Inc. shares jumped 17.7% in pre-market trade Wednesday after the company announced its chemotherapy-associated nausea and vomiting treatment had been approved by the Food and Drug Administration. The treatment, Sustol, works for five days, according to the company, while other such treatments are "generally effective for 48 hours or less." Shares rose as much as 26% in Wednesday pre-market trade. Heron Therapeutics shares rose 19.7% over the last three months, compared with a 4.7% rise in the S&P 500 .
Continue Reading Below
Copyright © 2016 MarketWatch, Inc.